Phase 2 N=19 Topical Antibiotics in Chronic Rhinosinusitis
Chronic Rhinosinusitis (Diagnosis)
Primary: Subjects Who Developed Antibiotic Resistance Organisms — 0; 0; 1; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=313 Evaluation of the Ottawa Model for Smoking Cessation in Diabetes Education Programs
Pre-diabetic · Diabetic Type II Mellitus
Primary: Percentage of Participants Who Self Report of Not Smoking (Even a Puff) in the Last 7 Days + CO <10ppm — 3; 22 Participants
Phase 2 N=62 Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery
Colorectal Cancer
Primary: Percentage of Participants in Objective Response (Partial or Complete Responses) — 47.5 percentage of participants
Phase 2 N=35 A Study to Evaluate SAGE-217 in Participants With Bipolar I/II Disorder With a Current Major Depressive Episode
Bipolar Disorder I · Bipolar Disorder II · Major Depressive Episode
Primary: Part A: Number of Participants With at Least One Treatment-Emergent Adverse Events (TEAEs) — 16 Participants
Phase 2 N=26 Pupil Dilation for Treatment of IFIS
Intraoperative Floppy Iris Syndrome
Primary: Pupil Dilation Sized of the Treated Eye Compared to the Non-treated Eye — 6.76; 7.17 millimeters
Phase 2 N=85 Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19
COVID-19
Primary: COVID Ordinal Outcomes Scale at 14 Days — 2.0; 2.0 score on a scale
Phase 3 N=660 Study of 10-valent Pneumococcal Conjugate Vaccine (Pneumosil) Administered in a 2+1 Schedule to Healthy Infants
Pneumonia, Pneumococcal
Primary: Geometric Mean Concentration (GMC) of Serotype-specific Immunoglobulin G (IgG) Antibodies Four Weeks Post-Booster — 8.45; 2.90; 5.87; 1.54 μg/mL
Phase 2 N=140 Study of Efficacy and Safety of MAS825 in Patients With COVID-19
COVID-19 Pneumonia, Impaired Respiratory Function
Primary: APACHE II Severity of Disease Score on Day 15 or on the Day of Discharge (Whichever is Earlier) — 14.5; 13.5 Score on a scale — p=0.33
Phase 3 N=37 Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Adults With Chronic HCV Infection and Compensated Cirrhosis
Hepatitis C Virus Infection
Primary: Percentage of Participants With Sustained Virologic Response (SVR) < Lower Limit of Quantification (LLOQ) 12 Weeks After Discontinuation of Treatment (SVR12) — 100.0…
Phase 4 N=161 Assessing Efficacy of Intravenous Acetaminophen for Perioperative Pain Control for Oocyte Retrieval
Infertility, Female · Pain, Postoperative
Primary: Post-operative Pain Score Difference 10 Mins From Pre-operative — 1.3; 1.3; 1.8 score on a scale
Phase 3 N=506 Efficacy of Tranexamic Acid in Preventing Postpartum Haemorrhage After Elective Caesarean Section
Post Partum Hemorrhage
Primary: Number of Participants With Postpartum Haemorrhage (PPH) — 48; 54; 56; 71 Participants — p=0.549
Phase 3 N=382 LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Heavy Menstrual Bleeding · Uterine Fibroid
Primary: Percentage Of Participants Who Achieved A Menstrual Blood Loss (MBL) Volume Of < 80 mL And A ≥ 50% Reduction From Baseline MBL Volume With Relugolix Plus E2/NETA — 71.2…
N/A N=16 Postmarket Clinical Follow-up Study to Confirm the Performance of the Wearable Pulse-Oximeter BrOxy M (SOMBRERO)
Laboratory Testing on Healthy Volunteers to Verify SpO2 and Heart Rate (HR) Accuracy of BrOxy M
Primary: Accuracy of SpO2 Measurement at 80-100% SpO2 — 2.7 A(RMS) - % — p=0.31
Phase 4 N=100 HIV Non-Occupational Post-Exposure Prophylaxis
Human Immunodeficiency Virus
Primary: Number of Adverse Event Occurrences — 38; 28; 28; 14 events
Phase 1 N=80 COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients With Pneumonia Caused by SARS-CoV-2.
COVID-19
Primary: Participants With Serious Adverse Events. — 12; 15 Participants